ArticleMayo Clinic proceedings. Innovations, quality & outcomes2020
Pharmacist-Driven MRSA Nasal PCR Screening and the Duration of Empirical Vancomycin Therapy for Suspected MRSA Respiratory Tract Infections.
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06272994 (Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc)
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- A Quality Improvement Project to Increase Pharmacist-Initiated Methicillin ResistantThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Implementation of an automated methicillin-resistantAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Article
- Antibiotic de-escalation in pneumonia with pharmacist education and ordering of methicillin-resistantEuropean journal of hospital pharmacy : science and practice · 2024Article
- Swab Testing to Optimize Pneumonia treatment with empiric Vancomycin (STOP-Vanc): study protocol for a randomized controlled trial.Research square · 2024Article
- Performance of Methicillin-ResistantThe Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2023Article
- Evaluation of Anti-Methicillin-ResistantPharmacy (Basel, Switzerland) · 2023Article
- Antimicrobial Stewardship Techniques for Critically Ill Patients with Pneumonia.Antibiotics (Basel, Switzerland) · 2023Review
- Change in Methicillin-ResistantOchsner journal · 2023Article
- Evaluation of the Negative Predictive Value of Methicillin-ResistantInfection and drug resistance · 2022Article
- Effect of rapid methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction screening on vancomycin use in the intensive care unit.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the effect of a pharmacist-driven, polymerase chain reaction (PCR)-based nasal screening protocol for methicillin-resistant PATIENTS AND
methodsFrom July 8, 2017, through January 31, 2019, we performed a retrospective, multicenter, preimplementation-postimplementation study. Patients with a vancomycin order to treat lower respiratory tract infection (LRTI) underwent MRSA PCR screening; tests were ordered by health care providers, including physicians, physician assistants, and advanced practice registered nurses. During the preimplementation period (July 8, 2017, through September 30, 2018), pharmacists could order MRSA PCR screening only after receiving a verbal order from a health care provider. During the postimplementation period (October 1, 2018, through January 31, 2019), a collaborative practice agreement allowed pharmacists to order MRSA PCR screening tests.
resultsThe preimplementation group included 241 patients, and the postimplementation group included 74 patients. Of these patients, 124 in the preimplementation group and 62 in the postimplementation group received MRSA PCR screening. Twenty patients (16.1%) in the preimplementation group and 9 (14.5%) in the postimplementation group had a positive MRSA PCR screening test result (between-group difference, 1.6%;
conclusionVancomycin therapy carries a risk of adverse events and may increase health care costs. A pharmacist-driven protocol for MRSA nasal swab PCR screening effectively reduces the duration of vancomycin therapy for patients with lower respiratory tract infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.